These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15185895)

  • 41. Atrial fibrillation and anticoagulation.
    Garnier LF; Rouesnel P; Espitalier F
    Arch Mal Coeur Vaiss; 2004 Oct; 97(10):1001-5. PubMed ID: 16008178
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New options in the treatment of atrial fibrillation].
    Völler H
    Dtsch Med Wochenschr; 2013 Dec; 138(50):2579. PubMed ID: 24301489
    [No Abstract]   [Full Text] [Related]  

  • 43. Rate control for atrial fibrillation: one drug or two?
    Segal OR
    Postgrad Med J; 2009 Jun; 85(1004):281-2. PubMed ID: 19528299
    [No Abstract]   [Full Text] [Related]  

  • 44. Oral anticoagulant therapy in patients with atrial fibrillation.
    Pengo V
    Semin Vasc Med; 2003 Aug; 3(3):333-8. PubMed ID: 15199467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Atrial fibrillation in the elderly.
    Fang MC; Chen J; Rich MW
    Am J Med; 2007 Jun; 120(6):481-7. PubMed ID: 17524745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identifying AF patients at risk of stroke: can prothrombotic indices improve things?
    Watson T; Lip GY
    Int J Cardiol; 2008 Jun; 126(3):299-301. PubMed ID: 18077017
    [No Abstract]   [Full Text] [Related]  

  • 48. Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation.
    Anderson DR; Gardner MJ; Putnam W; Jassal D; Brownell B; Flowerdew G; Nagpal S; Thompson K; Cox JL
    Can J Cardiol; 2005 Mar; 21(3):257-66. PubMed ID: 15776115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ventricular proarrhythmic effects of atrial fibrillation are modulated by depolarization and repolarization anomalies in patients with left ventricular dysfunction.
    Lemola K; Khan R; Nattel S; Talajic M; Roy D; Guerra PG; Lemola S; Dubuc M; Thibault B; Macle L; Khairy P
    Pacing Clin Electrophysiol; 2009 Jan; 32(1):99-105. PubMed ID: 19140919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study.
    Pérez-Gómez F; Alegría E; Berjón J; Iriarte JA; Zumalde J; Salvador A; Mataix L;
    J Am Coll Cardiol; 2004 Oct; 44(8):1557-66. PubMed ID: 15489085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Flaker GC; Belew K; Beckman K; Vidaillet H; Kron J; Safford R; Mickel M; Barrell P;
    Am Heart J; 2005 Apr; 149(4):657-63. PubMed ID: 15990749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticoagulation of atrial fibrillation in older people: a clinical practice observational study.
    Abdelhafiz AH; Wheeldon NM
    J Am Geriatr Soc; 2006 Jan; 54(1):176-7. PubMed ID: 16420226
    [No Abstract]   [Full Text] [Related]  

  • 53. Predicting thromboembolism and selecting patients for anticoagulant therapy in atrial fibrillation.
    Weintraub WS
    J Am Coll Cardiol; 2008 Feb; 51(8):816-7. PubMed ID: 18294565
    [No Abstract]   [Full Text] [Related]  

  • 54. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
    Ruiz-Nodar JM; Marín F; Hurtado JA; Valencia J; Pinar E; Pineda J; Gimeno JR; Sogorb F; Valdés M; Lip GY
    J Am Coll Cardiol; 2008 Feb; 51(8):818-25. PubMed ID: 18294566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Anticoagulants in non-rheumatic atrial fibrillation].
    van Gennip A; Hellemons-Boode B; Krebber T; Langenberg-Ledeboer M
    Ned Tijdschr Geneeskd; 1992 Jan; 136(4):195-6. PubMed ID: 1736135
    [No Abstract]   [Full Text] [Related]  

  • 57. Prevention of thromboembolic complications in patients with atrial fibrillation.
    Spiezia L; Prandoni P
    Minerva Cardioangiol; 2008 Dec; 56(6):643-52. PubMed ID: 19092739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Left ventricular diastolic dysfunction and thromboembolic risk in atrial fibrillation: diastolic dysfunction and thromboembolic risk in AF.
    Kosiuk J; Breithardt O; Bode K; Kornej J; Arya A; Gaspar T; Hindricks G; Bollmann A
    Int J Cardiol; 2013 Sep; 168(1):547-8. PubMed ID: 23453879
    [No Abstract]   [Full Text] [Related]  

  • 59. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials.
    de Denus S; Tardif JC; White M; Bourassa MG; Racine N; Levesque S; Ducharme A
    Am Heart J; 2006 Oct; 152(4):705-12. PubMed ID: 16996842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
    Douketis JD; Johnson JA; Turpie AG
    Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.